Good evening :)
$
₹
Beyond Air Inc

Beyond Air Inc

XAIR

NASDAQ
Asset Logo

Beyond Air Inc

XAIR

NASDAQ
$2.170.18% (-0.00)
$
₹
$2.170.18% (-0.00)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Medical Devices

Micro Cap

With a market cap of $3.9M the stock is ranked 6006

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

1.11
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-66.1
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 2 analysts reports

Buy
2 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+817.43%

Earnings Growth

-822.73%

Rev. Growth

—

See Detailed Forecast

Company Profile

Company Profile

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Abbott Laboratories
ABT
Abbott Laboratories
P/E Ratio
42.94
42.94
1Y Return
7.25%
7.25%
Buy Reco %
82.14
82.14
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
P/E Ratio
58.29
58.29
1Y Return
12.11%
12.11%
Buy Reco %
76.47
76.47
Danaher Corporation
DHR
Danaher Corporation
P/E Ratio
38.89
38.89
1Y Return
10.7%
10.7%
Buy Reco %
83.33
83.33
Medtronic PLC
MDT
Medtronic PLC
P/E Ratio
25.78
25.78
1Y Return
15.97%
15.97%
Buy Reco %
66.66
66.66
Stryker Corporation
SYK
Stryker Corporation
P/E Ratio
36.17
36.17
1Y Return
6.31%
6.31%
Buy Reco %
76.66
76.66
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 817.43% growth, versus a trailing 3-year CAGR of -62.61%.

2026
Current$2.18Baseline
Analyst Target - 1 year
Target$20+817.43%

All values in $

202220232024202520262027$37.17$72.37$107.58Target+817.43%
2026
Current$2.18Baseline
Analyst Target - 1 year
Target$20+817.43%

All values in $

Earnings Per Share Forecast

Earnings Per Share Forecast

2026
Current$-4.4Baseline
Forecast for Mar 2027
High$-40.6-822.73%
Average$-40.6-822.73%
Low$-40.6-822.73%

All values in $

202220232024202520262027-19.93-24.67-29.56-14.09-4.4Low-822.73%Average-822.73%High-822.73%
2026
Current$-4.4Baseline
Forecast for Mar 2027
High$-40.6-822.73%
Average$-40.6-822.73%
Low$-40.6-822.73%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

1.8
-7.9
2.1
-7.3
1.9
-10.2
1.7
-7.9
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0.470.680.791.071.151.761.812.191.901.76
Net Income-13.70-12.20-13.35-13.03-8.03-7.69-7.94-7.33-10.28-7.93
Net Profit Margin-2916.38%-1786.38%-1673.93%-1215.67%-697.39%-436.98%-436.74%-334.36%-539.17%-448.81%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareMedical Devices

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Beyond Air Inc -1.11-
Abbott Laboratories42.943.701.56
Intuitive Surgical Inc58.299.742.04
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare XAIR with any stock or ETF
Compare XAIR with any stock or ETF
Comparing from
XAIR
ABT
ISRG
Loading...

Frequently asked questions

  1. Beyond Air Inc (XAIR) share price today is $2.17 as of November 6, 2026 at 10:18 PM IST. The stock touched a day high of $2.25 and a day low of $2.17.

  2. Beyond Air Inc stock trades on NASDAQ under the ticker symbol XAIR.

  3. Beyond Air Inc's market capitalization is $3.88M as of November 6, 2026 at 10:18 PM IST.

  4. Beyond Air Inc's price-to-earnings (P/E) ratio is N/A as of November 6, 2026.

  5. Beyond Air Inc's price-to-book (P/B) ratio is 1.11 as of November 6, 2026.

  6. Yes, You can buy Beyond Air Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Beyond Air Inc shares in three steps: 1. Search Beyond Air Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Beyond Air Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Beyond Air Inc (XAIR) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 4.5955 shares at the current price of $2.17.

Loading...